Old Web
English
Sign In
Acemap
>
authorDetail
>
Yonggui Hong
Yonggui Hong
esophageal squamous cell carcinoma
open label
Medicine
Oncology
Cisplatin
4
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
659 AN SINGLE-ARM OPEN-LABEL PHASE II STUDY OF CAMRELIZUMAB PLUS APATINIB AS SECOND-LINE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
2021
Diseases of The Esophagus
Feng Wang
Qingxia Fan
Jun-Sheng Wang
Tao Wu
Yonggui Hong
Xiangrui Meng
Zhonghai Ren
Yanzhen Guo
Xiuli Yang
Pei Shi
JiaMei Yang
Xianzhe Yin
Zhiquan Luo
Jin Xia
Yue Zhou
Enjie Liu
Guozhong Jiang
Show All
Source
Cite
Save
Citations (0)
Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
2021
Journal of Clinical Oncology
Junsheng Wang
Suxia Luo
Ning Li
Tao Wu
Yonggui Hong
Yanzhen Guo
Yufeng Cheng
Baosheng Li
Bingxu Tan
Show All
Source
Cite
Save
Citations (0)
Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial.
2021
Journal of Clinical Oncology
Junsheng Wang
Tao Wu
Suxia Luo
Ning Li
Yonggui Hong
Yanzhen Guo
Yufeng Cheng
Baosheng Li
Show All
Source
Cite
Save
Citations (0)
Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
2021
Journal of Clinical Oncology
Feng Wang
Junsheng Wang
Tao Wu
Yonggui Hong
Xiangrui Meng
Zhonghai Ren
Yanzhen Guo
Xiuli Yang
Pei Shi
JiaMei Yang
Qingxia Fan
Show All
Source
Cite
Save
Citations (0)
1